0 0 0 0 0 0 0 0
Thanks for submitting the form.
Stockreport

NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]

NovoCure Limited - Ordinary Shares (NVCR)  More Company Research Source: Seeking Alpha
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Market data suggests faster growth for specialty oncology treatments, providing tailwinds for NovoCure's business. The core business is strong, with accelerated revenue growth and pursuit of new treatments, leading to significant upside potential. I am updating my previous analysis on NovoCure Limited ( NASDAQ: NVCR ) in light of Q1 2024 earnings which were released pre-market on Thursday, May 2nd. I previously rated NovoCure a buy for the following reasons: Core Recommended For You Recommended For You About NVCR Stock [Read more]

IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Stockreport

NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Market data suggests faster growth for specialty oncology treatments, providing tailwinds for NovoCure's business. The core business is strong, with accelerated revenue growth and pursuit of new treatments, leading to significant upside potential. I am updating my previous analysis on NovoCure Limited ( NASDAQ: NVCR ) in light of Q1 2024 earnings which were released pre-market on Thursday, May 2nd. I previously rated NovoCure a buy for the following reasons: Core Recommended For You Recommended For You About NVCR Stock [Read more]

IMPACT SNAPSHOT
EVENT TIME:
NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS